NR1H4 and metabolic dysfunction-associated steatohepatitis: Non-steroidal (e.g., PX-20606, GS-9674) FXR agonists have demonstrated efficacy in reducing portal pressure in models of toxic, cholestatic, and NASH-induced cirrhosis, without adverse effects on systemic hemodynamics [219].